HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 434, Issue 1, 2013, Pages 81-86

  Cheng, Jung Chien ^a   Qiu, Xin ^a   Chang, Hsun Ming ^a   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

E cadherin; EGF; HER2; Ovarian cancer

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

BENZOTHIAZOLES; CADHERINS; CELL LINE, TUMOR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS; TYRPHOSTINS; UP-REGULATION;

GASTROPODA;

EID: 84876784697     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.062     Document Type: Article

References (31)

1. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
2. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
3. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16.
4. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J. 1997, 16:1647-1655.
5. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000, 19:3159-3167.
6. Siwak D.R., Carey M., Hennessy B.T., Nguyen C.T., McGahren Murray M.J., Nolden L., Mills G.B. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J. Oncol. 2010, 2010:568938.
7. Sheng Q., Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br. J. Cancer 2011, 104:1241-1245.
8. Lafky J.M., Wilken J.A., Baron A.T., Maihle N.J. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim. Biophys. Acta 2008, 1785:232-265.
9. Bartlett J.M., Langdon S.P., Simpson B.J., Stewart M., Katsaros D., Sismondi P., Love S., Scott W.N., Williams A.R., Lessells A.M., Macleod K.G., Smyth J.F., Miller W.R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 1996, 73:301-306.
10. Niikura H., Sasano H., Sato S., Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 1997, 16:60-68.
11. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21:2787-2799.
12. Farley J., Fuchiuji S., Darcy K.M., Tian C., Hoskins W.J., McGuire W.P., Hanjani P., Warshal D., Greer B.E., Belinson J., Birrer M.J. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol. Oncol. 2009, 113:341-347.
13. Tuefferd M., Couturier J., Penault-Llorca F., Vincent-Salomon A., Broet P., Guastalla J.P., Allouache D., Combe M., Weber B., Pujade-Lauraine E., Camilleri-Broet S. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007, 2:e1138.
14. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus-Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Embo J. 1996, 15:254-264.
15. Lenferink A.E., Pinkas-Kramarski R., van de Poll M.L., van Vugt M.J., Klapper L.N., Tzahar E., Waterman H., Sela M., van Zoelen E.J., Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. Embo J. 1998, 17:3385-3397.
16. Franklin M.C., Carey K.D., Vajdos F.F., Leahy D.J., de Vos A.M., Sliwkowski M.X. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317-328.
17. Sims A.H., Zweemer A.J., Nagumo Y., Faratian D., Muir M., Dodds M., Um I., Kay C., Hasmann M., Harrison D.J., Langdon S.P. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br. J. Cancer 2012, 106:1779-1789.
18. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
19. Cheng J.C., Klausen C., Leung P.C. Hydrogen peroxide mediates EGF-induced down-regulation of E-cadherin expression via p38 MAPK and snail in human ovarian cancer cells. Mol. Endocrinol. 2010, 24:1569-1580.
20. Cheng J.C., Klausen C., Leung P.C. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013, 329:197-206.
21. Cheng J.C., Chang H.M., Leung P.C. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene 2013, 32:1041-1049.
22. D'Souza B., Taylor-Papadimitriou J. Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc. Natl. Acad. Sci. USA 1994, 91:7202-7206.
23. Woo M.M., Salamanca C.M., Minor A., Auersperg N. An improved assay to quantitate the invasiveness of cells in modified Boyden chambers. In Vitro Cell Dev. Biol. Anim. 2007, 43:7-9.
24. DiGiovanna M.P., Lerman M.A., Coffey R.J., Muller W.J., Cardiff R.D., Stern D.F. Active signaling by Neu in transgenic mice. Oncogene 1998, 17:1877-1884.
25. Siegel P.M., Ryan E.D., Cardiff R.D., Muller W.J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. Embo J. 1999, 18:2149-2164.
26. Muller W.J., Arteaga C.L., Muthuswamy S.K., Siegel P.M., Webster M.A., Cardiff R.D., Meise K.S., Li F., Halter S.A., Coffey R.J. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell Biol. 1996, 16:5726-5736.
27. Lu C., Speers C., Zhang Y., Xu X., Hill J., Steinbis E., Celestino J., Shen Q., Kim H., Hilsenbeck S., Mohsin S.K., Wakeling A., Osborne C.K., Brown P.H. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J. Natl. Cancer Inst. 2003, 95:1825-1833.
28. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., Moore D., Thor A.D. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. 2005, 23:1152-1160.
29. Wiseman S.M., Makretsov N., Nielsen T.O., Gilks B., Yorida E., Cheang M., Turbin D., Gelmon K., Huntsman D.G. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005, 103:1770-1777.
30. Brabender J., Danenberg K.D., Metzger R., Schneider P.M., Park J., Salonga D., Holscher A.H., Danenberg P.V. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. 2001, 7:1850-1855.
31. Lassus H., Sihto H., Leminen A., Joensuu H., Isola J., Nupponen N.N., Butzow R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. (Berl.) 2006, 84:671-681.